Related Experiment Video

Updated: Jan 15, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.2K

Beyond Pathology: α-Synuclein Homeostasis and Three Principles to Guide Research

Alberto J Espay1, Andrew J Lees2

  • 1James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA.

Movement Disorders Clinical Practice
|October 15, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Parkinson's diseasegain of functionloss of functionα‐synuclein

More Related Videos

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

18.0K
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.6K

Related Experiment Videos

Last Updated: Jan 15, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.2K
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

18.0K
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.6K

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

11.6K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.6K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Neural Regulation01:37

Neural Regulation

43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K

Articles linked to this work by shared authors, journal, and citation graph.

Comparison of double-blind and open-label decline rates in lecanemab and donanemab trials in Alzheimer's disease.

BMJ neurology open·2026

Defining the underlying pathology of corticobasal syndrome using clinical features and biomarkers.

Brain : a journal of neurology·2026

Bridging the global Parkinson's divide: Technology as a structural solution for equitable and brain health-integrated care.

Journal of Parkinson's disease·2026

The Charcot shower.

Arquivos de neuro-psiquiatria·2026

Systematic review of movement disorders mislabeled as functional: when incongruence misleads.

Journal of neurology·2026

A Pioneering 1915 Film on Movement Disorders in Spain: Parkinsonism, Huntington's Disease, and Paradoxical Kinesia.

Movement disorders : official journal of the Movement Disorder Society·2026

Comparative Analysis of L-Dopa and Deep Brain Stimulation on Bradykinesia Components in Parkinson's Disease.

Movement disorders clinical practice·2026

Multi-Domain Gait Profiling in Idiopathic Normal Pressure Hydrocephalus: Differentiating Fall Patterns and Assessing Shunt Responsiveness.

Movement disorders clinical practice·2026

DYT-PRKRA Dystonia-Parkinsonism with Pathological Startle: Expanding the Phenotype of PRKRA-Related Disease.

Movement disorders clinical practice·2026

Anti-Amphiphysin Stiff-Person Spectrum Disorders: A Systematic Review and Case Series Featuring an Unusual Isolated Upper-Limb Presentation.

Movement disorders clinical practice·2026

Exercise and Motor Complications in Parkinson's Disease: A Systematic Review and Meta-Analysis.

Movement disorders clinical practice·2026

Clinical Approach to Impulse Control-Related Behavioral Disorders in Parkinson's Disease: A Scoping Review.

Movement disorders clinical practice·2026

Targeting the NLRP3 inflammasome pathway associated with neuroinflammation mediated Alzheimer's disease: pre-clinical and clinical status of emerging therapeutics.

Expert opinion on therapeutic targets·2026

Relationship between retinal nerve fibre thickness, suprasellar extension and post-operative visual outcome in pituitary macroadenoma.

International journal of ophthalmology·2026

Closed-loop bioelectronic block of stellate ganglia reduces neurotransmitter release and improves recovery following programmed ventricular pacing.

Frontiers in bioengineering and biotechnology·2026

Serum IL-6 and functional outcome after endovascular therapy: the mediating role of infarct volume growth in acute ischemic stroke.

Frontiers in immunology·2026

NR1D1-Mediated Suppression of JAK1/STAT3 Signaling Contributes to the Therapeutic Effects of Triptolide in Rheumatoid Arthritis.

Mediators of inflammation·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us